• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Can Azithromycin be Used as an Alternative to Erythromycin for PPROM?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • US PPROM recommendations (see ‘Related ObG Topics’, below)
    • IV ampicillin [2 g every 6 hours] and erythromycin [250 mg every 6 hours] for 48 hours followed by oral amoxicillin [250 mg every 8 hours] and erythromycin base [333 mg every 8 hours] for an additional 5 days (7 days total)
  • Azithromycin has the following benefits compared to erythromycin
    • Fewer side effects | Cheaper | Availability
  • Navathe et al. (AJOG, 2019) compared erythromycin and azithromycin for PPROM

METHODS:

  • Multicenter, retrospective cohort study
  • Participants
    • Singleton pregnancies | Confirmed PROM | 23w0d -33w6d
  • Antibiotic regimens
    • Azithromycin 1 day group: Azithromycin 1000 mg po once
    • Azithromycin 5 day group: Azithromycin 500 mg po once, followed by azithromycin 250 mg po daily for 4 days
    • Azithromycin 7 day group: Azithromycin 500 mg IV for 2 days, followed by azithromycin 500 mg po daily for 5 days
    • Erythromycin group: IV for 2 days followed by erythromycin po for 5 days
  • Regimen based on institutional policy and/or medication availability
  • All patients received ampicillin IV for 2 days followed by amoxicillin po for 5 days
  • Primary outcome
    • Latency from PPROM to delivery
  • Secondary outcomes
    • Chorioamnionitis | GA at delivery | Vaginal delivery | Stillbirth
    • Neonatal outcomes (e.g., IVH, NEC, RDS, sepsis, death)

RESULTS:

  • 453 patients met inclusion criteria
    • Median GA at delivery: 30 weeks
  • No difference in median latency of azithromycin groups compared to erythromycin after adjusting for demographic variables (P=0.99)
    • Azithromycin 1 day: 4.9 days for (95% CI, 3.3–6.4)
    • Azithromycin 5 days: 5.0 days for (95% CI, 3.9–6.1)
    • Azithromycin 7 days: 4.9 days for (95% CI, 2.8–7.0)
    • Erythromycin: (5.1 days for 95% CI, 3.9–6.4)
  • No difference in secondary outcomes, including chorioamnionitis except for RDS
    • RDS was more common in azithromycin 5 day group (44%) compared to the azithromycin 1 day group (29%) and the erythromycin group (29%) ; P=0.005

CONCLUSION:

  • There was no difference in primary outcome (latency) or other secondary outcomes except for RDS in the 5 day azithromycin group
  • The authors suggest that azithromycin is a potential alternative for PPROM treatment if erythromycin is not an option (contraindicated or unavailable)

Learn More – Primary Sources:

Azithromycin vs erythromycin for the management of preterm premature rupture of membranes

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

ACOG Guidance Update: Diagnosis and Management of PROM (Prelabor Rupture of Membranes)
Should Tocolytics Be Used Following PPROM?
What is the Best Course of Action Following PPROM Between 24 and 37 Weeks?
Can Azithromycin Be Used in Place of Erythromycin for Preterm PROM?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site